Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.42 |
| ▸ | STAT3 | P40763 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064521 | 1.00 | SCN9A (0.49) | SCN9ARAB9AMGLLNPC1TNF | |
| SCHEMBL3064516 | 1.00 | SCN9A (0.49) | SCN9ARAB9AMGLLNPC1TNF | |
| SCHEMBL10181162 | 0.89 | SCN9A (0.49) | SCN9AMGLLSTAT3 | |
| SCHEMBL3708466 | 0.89 | SCN9A (0.49) | SCN9AMGLLSTAT3 | |
| SCHEMBL10181164 | 0.89 | SCN9A (0.49) | SCN9AMGLLSTAT3 | |
| SCHEMBL3057206 | 0.88 | SCN9A (0.56) | SCN9ARAB9ANPC1TNFNOD1 | |
| Oxalic Acid SCHEMBL3050859 | 0.87 | STAT3 (0.50) | MGLLHIF1AEPAS1STAT3 | |
| Oxalic Acid SCHEMBL3050863 | 0.87 | STAT3 (0.50) | MGLLHIF1AEPAS1STAT3 | |
| Oxalic Acid SCHEMBL3058185 | 0.87 | STAT3 (0.50) | MGLLHIF1AEPAS1STAT3 | |
| SCHEMBL3068127 | 0.85 | SCN9A (0.59) | SCN9ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | SCN9A 2616/4885RAB9A 2502/4885MGLL 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.